Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$18.8MCash on Hand
22.7mo Cash Runway
Follow ELAB by emailGet an email when ELAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELAB, unsubscribe in one click. Privacy
📣 What ELAB Says Is Next
during 2026 · “Forward -looking statements herein relate to the plans, strategy, objectives and other aspects of the anticipated future operations and the financial, development and operati ng plans and results of the Company and include statements regarding, among others, the future financial performance of the Company, contractual arrangements relating to future operations, scheduled operationa l activities during 2026 and beyond.”
Company press release, Oct 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Clinical trial PMGC Holdings (ELAB) signed a $300,000 consulting deal with IR Agency LLC for up to three months of investor relations services, and a C$185,000 digital marketing agreement with Senergy Communications Capital for about one month. Form 8-K · SEC filing · Press release
Nov 2, 2026 ·
Financing PMGC Holdings agreed on October 30, 2026 to subscribe for US$1,845,000 of secured, non-interest-bearing debentures of Nuclea Energy Canada, which will fund its Moltex Energy asset acquisition. The company receives a US$45,000 finance fee withheld at closing, with proceeds held in escrow. Form 8-K · SEC filing
Oct 28, 2026 ·
PMGC Holdings (Nasdaq: ELAB), doing business as NorthStrive Holdings, furnished an investor presentation (Exhibit 99.1) and a Maritime Defense Technology presentation (Exhibit 99.2) for use in investor meetings. The filing reports no new financial results or deal terms. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Deal PMGC Holdings and subsidiary NorthStrive Biosciences entered a payment agreement with Longevity Health Holdings securing royalties from the January 2025 Elevai Skincare sale. Longevity acknowledged a 2025 royalty of $94,937, with $10,000 monthly installments starting October 15, 2026 through August 2031. Form 8-K · SEC filing · Press release
Sep 2, 2026 ·
Deal Amended its Development and License Agreement with Yuva Biosciences to launch a three-phase, roughly 6-month Expansion Program to advance four AI-discovered compounds toward lead nomination. Form 8-K · SEC filing · Press release
Aug 27, 2026 ·
Deal PMGC Holdings entered a five-year, royalty-free trademark license with NorthStrive Companies, wholly owned by Chairman Braeden Lichti, for $1.00. It also agreed with Streeterville Capital to exchange a $1,071,339.8 pre-paid purchase balance for 80,000 common shares. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ELAB holds $18.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations,
an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:68 · High
Cash runway 23 months +8
ATM program on file since Nov 2023 +15
Shelf registration (S-3, Jan 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 1,168,935 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ELAB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.